Description

Etopozid (etoposide) concentrate for infusions 20 mg/ml. 5 ml. (100 mg.) vial №1

Ingredients:

Each 5 ml vial contains 100 mg of etoposide as the active ingredient. Other ingredients include citric acid, polysorbate 80, and sodium chloride.

Dosage:

The dosage of Etopozid (etoposide) concentrate for infusions is determined by a healthcare provider based on the patient’s condition, weight, and other factors. It is administered intravenously over a specific period as directed.

Indications:

Etopozid (etoposide) concentrate for infusions is indicated for the treatment of various types of cancers, including lung cancer, testicular cancer, and lymphomas. It works by interfering with the growth of cancer cells.

Contraindications:

This medication is contraindicated in patients with a known hypersensitivity to etoposide or any of the other ingredients. It should not be used in pregnant women due to potential harm to the fetus.

Directions:

Etopozid (etoposide) concentrate for infusions should only be administered by healthcare professionals experienced in chemotherapy treatments. The infusion should be given slowly to minimize the risk of side effects.

Scientific Evidence:

Etoposide has been extensively studied in various clinical trials for its efficacy in treating different types of cancers. Research published in the Journal of Clinical Oncology demonstrated the effectiveness of etoposide in combination therapies for small cell lung cancer (SCLC). The study showed significant improvements in overall survival rates and tumor response compared to standard treatments.

Additional Information:

In addition to its use in solid tumors, etoposide has also shown promising results in the treatment of hematologic malignancies. Studies have highlighted its role in the management of relapsed or refractory lymphomas and leukemias. The drug’s mechanism of action involves inhibiting topoisomerase II, a key enzyme involved in DNA replication, leading to cancer cell death.

Overall, Etopozid (etoposide) concentrate for infusions 20 mg/ml. 5 ml. (100 mg.) vial №1 is a vital component in the treatment of various cancers, offering a well-established efficacy profile supported by scientific evidence and clinical trials.